Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (388)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01825213 | Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT | completed | — | 10 | Massachusetts General HospitalOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | terminated | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients(SLAMF3) | withdrawn | — | 0 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01316679 | An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423 | completed | — | 87 | Vanderbilt University Medical CenterOTHER | 0 | Apr 12, 2017 | clinicaltrials |
| NCT03110068 | Preoperative Estimation of Microvascular Invasion in Hepatocellular Carcinoma | unknown | — | 370 | Ming KuangOTHER | 0 | Apr 12, 2017 | clinicaltrials |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | completed | Phase 3 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | terminated | Phase 3 | 35 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT03088423 | HCC Response Assessment by MRI After SBRT | completed | — | 35 | Institut de Cancérologie de LorraineOTHER | 0 | Mar 23, 2017 | clinicaltrials |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | terminated | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT03082378 | Central Obesity and Hepatocellular Carcinoma | unknown | — | 200 | Chinese PLA General HospitalOTHER | 1 | Mar 17, 2017 | clinicaltrials |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | completed | Phase 2 | 566 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 16, 2017 | clinicaltrials |
| NCT01869088 | TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma | unknown | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01804829 | Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. | completed | Phase 3 | 80 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01522937 | A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer | completed | Phase 2 | 94 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01507064 | Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma(LANEX) | completed | Phase 2 | 40 | Cardarelli HospitalOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01656265 | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 24 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT03069508 | Clemizole HCl for Subjects With Hepatocellular Carcinoma | unknown | Phase 2 | 12 | Eiger Group International, Inc.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT03066557 | Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma | unknown | N/A | 80 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Feb 28, 2017 | clinicaltrials |
| NCT02936856 | Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications(RDSA) | unknown | N/A | 200 | Guangxi Medical UniversityOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02956772 | Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 190 | Hunan Provincial People's HospitalOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01668134 | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 28 | Washington University School of MedicineOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | terminated | Phase 2 | 19 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02783261 | Prospective Post Y90 Liver Hypertrophy | unknown | — | 25 | Singapore General HospitalOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT01273662 | Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 45 | National Taiwan University HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03048123 | HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B | completed | Phase 2 | 79 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03046979 | Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)(HCC) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00273312 | Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 7, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02447679 | Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence | completed | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03045419 | Added Value of Gadoxetic Acid-enhanced Liver MRI | completed | — | 130 | Seoul National University HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01954745 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | completed | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | terminated | — | 13 | Stanford UniversityOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00465023 | Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases | completed | N/A | 16 | Massachusetts General HospitalOTHER | 0 | Jan 20, 2017 | clinicaltrials |
| NCT01482442 | SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma(SARAH) | completed | Phase 3 | 496 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT02315989 | Early-Phase Safety of Proton Therapy Equipment | completed | N/A | 6 | Chang Gung Memorial HospitalOTHER | 1 | Jan 13, 2017 | clinicaltrials |
| NCT03020342 | HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC | unknown | — | 50 | National Taiwan University HospitalOTHER | 1 | Jan 13, 2017 | clinicaltrials |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | terminated | Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT01966133 | TACE as an Adjuvant Therapy After Hepatectomy for HCC | unknown | Phase 3 | 280 | Jia FanOTHER | 1 | Jan 9, 2017 | clinicaltrials |
| NCT03007212 | Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis | completed | Phase 4 | 30 | Ain Shams UniversityOTHER | 0 | Jan 2, 2017 | clinicaltrials |
| NCT02987699 | Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 28, 2016 | clinicaltrials |
| NCT01767597 | Application of HBV Rapid Tests as a Tool for Wide-Use Screening(OPTISCREEN-B) | completed | N/A | 1,000 | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'BaOTHER | 1 | Dec 13, 2016 | clinicaltrials |
| NCT01790633 | Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests(OPTISCREEN-III) | completed | N/A | 327 | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'BaOTHER | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02990351 | Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt | completed | — | 29 | Ain Shams UniversityOTHER | 0 | Dec 13, 2016 | clinicaltrials |
| NCT02985034 | Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT | completed | — | 77 | Seoul National University HospitalOTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Apr 18, 2017source: clinicaltrials